Urocortin: A beneficial or detrimental agent to endothelium?

Biochemical and Biophysical Research Communications

Volumn 371, Issue 3, 2008, Pages 345-349

  Yang, Cui ^a   Xu, Yinyan ^a   Li, Shengnan ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Corticotropin releasing factor; Endothelial dysfunction; Endothelium; Urocortin

Indexed keywords

ADRENOMEDULLIN; ANGIOTENSIN II; AUTACOID; BRADYKININ; CORTICOTROPIN RELEASING FACTOR RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; FREE RADICAL; HYDROGEN PEROXIDE; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; NATRIURETIC PEPTIDE RECEPTOR C; NITRIC OXIDE; PROSTACYCLIN; PROSTAGLANDIN; SUPEROXIDE DISMUTASE; THROMBOXANE A2; UROCORTIN; VASOCONSTRICTOR AGENT; VASODILATOR AGENT;

BLOOD VESSEL PERMEABILITY; BLOOD VESSEL WALL; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; DOWN REGULATION; ENDOTHELIAL DYSFUNCTION; EXPERIMENTAL RAT; HUMAN; MAST CELL DEGRANULATION; MOLECULAR BIOLOGY; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN FUNCTION; REPERFUSION INJURY; SHORT SURVEY; THROMBOGENESIS; THROMBOGENICITY; VASCULAR ENDOTHELIUM;

ANIMALS; CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; HUMANS; MICE; RATS; UROCORTINS;

EID: 43549121471     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2008.01.157     Document Type: Short Survey

References (46)

1. Vaughan J., Donaldson C., Bittencourt J., Perrin M.H., Lewis K., Sutton S., Chan R., Turnbull A.V., Lovejoy D., Rivier C., Rivier J., Sawchenko P.E., and Vale W. Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature 378 (1995) 287-292
2. Skelton K.H., Owens M.J., and Nemeroff C.B. The neurobiology of urocortin. Regul. Pept. 93 (2000) 85-92
3. Muramatsu Y., Fukushima K., Iino K., Totsune K., Takahashi K., Suzuki T., Hirasawa G., Takeyama J., Ito M., Nose M., Tashiro A., Hongo M., Oki Y., Nagura H., and Sasano H. Urocortin and corticotropin-releasing factor receptor expression in the human colonic mucosa. Peptides 21 (2000) 1799-1809
4. Brar B.K., Stephanou A., Okosi A., Lawrence K.M., Knight R.A., Marber M.S., and Latchman D.S. CRH-like peptides protect cardiac myocytes from lethal ischaemic injury. Mol. Cell Endocrinol. 158 (1999) 55-63
5. Petraglia F., Florio P., Gallo R., Simoncini T., Saviozzi M., Di Blasio A.M., Vaughan J., and Vale W. Human placenta and fetal membranes express human urocortin mRNA and peptide. J. Clin. Endocrinol. Metab. 81 (1996) 3807-3810
6. Bamberger C.M., Wald M., Bamberger A.M., Ergun S., Beil F.U., and Schulte H.M. Human lymphocytes produce urocortin, but not corticotropin releasing hormone. J. Clin. Endocrinol. Metab. 83 (1998) 708-711
7. Oki Y., Iwabuchi M., Masuzawa M., Watanabe F., Ozawa M., Iino K., Tominaga T., and Yoshimi T. Distribution and concentration of urocortin and effect of adrenalectomy on its content in rat hypothalamus. Life Sci. 62 (1998) 807-812
8. Parkes D.G., Vaughan J., Rivier J., Vale W., and May C.N. Cardiac inotropic actions of urocortin in conscious sheep. Am. J. Physiol. 272 (1997) H2115-H2122
9. + channels. Br. J. Pharmacol. 135 (2002) 1467-1476
10. Miki I., Seya K., Motomura S., and Furukawa K. Role of Corticotropin releasing factor receptor type 2 beta in urocortin-induced vasodilation of rat aortas. J. Pharmacol. Sci. 96 (2004) 170-176
11. Jain V., Longo M., Ali M., Saade G.R., Chwalisz K., and Garfield R.E. Expression of receptors for corticotropin-releasing factor in the vasculature of pregnant rats. J. Soc. Gynecol. Investig. 7 (2000) 153-160
12. Okosi A., Brar B.K., Chan M., D'Souza L., Smith E., Stephanou A., Latchman D.S., Chowdrey H.S., and Knight R.A. Expression and protective effects of urocortin in cardiac myocytes. Neuropeptides 32 (1998) 167-171
13. Tao J., Xu H., Yang C., Liu C.N., and Li S. Effect of urocortin on L-type calcium currents in adult rat ventricular myocytes. Pharmacol. Res. 50 (2004) 471-476
14. Xu H., Wang Y., Tao J., Yang C., Chen J., Wang H., and Li S. The cardioprotective peptide, urocortin, activates cardiac KATP channels in adult rat. Protein Pept. Lett. 13 (2006) 21-27
15. Huang Y., Yao X.Q., Lau C.W., Chan Y.C., Tsang S.Y., and Chan F.L. Urocortin and cardiovascular protection. Acta Pharmacol. Sin. 25 (2004) 257-265
16. Latchman D.S. Urocortin protects against ischemic injury via a MARK-dependent pathway. Trends Cardiovasc. Med. 11 (2001) 167-169
17. + channels in endothelium independent relaxation by urocortin in the rat coronary artery. Cardiovasc. Res. 57 (2003) 824-833
18. Lawrence K.M., Chanalaris A., Scarabelli T., Hubank M., Pasini E., Townsend P.A., Comini L., Ferrari R., Tinker A., Stephanou A., Knight R.A., and Latchman D.S. K(ATP) channel gene expression is induced by urocortin and mediates its cardioprotective effect. Circulation 106 (2002) 1556-1562
19. Liu C.N., Yang C., Liu X., and Li S. In vivo protective effects of urocortin on ischemia/reperfusion injury in rat heart via free radical mechanisms. Can. J. Physiol. Pharmacol. 83 (2005) 459-465
20. Lubomirov L., Gagov H., Petkova-Kirova P., Duridanova D., Kalentchuk V.U., and Schubert R. Urocortin relaxes rat tail arteries by a PKA-mediated reduction of the sensitivity of the contractile apparatus for calcium. Br. J. Pharmacol. 134 (2001) 1564-1570
21. Behrendt D., and Ganz P. Endothelial function: from vascular biology to clinical applications. Am. J. Cardiol. 90 (2002) 40L-48L
22. Ganz P., and Vita J.A. Testing endothelial vasomotor function: nitric oxide, a multipotent molecule. Circulation 108 (2003) 2049-2053
23. De Graaf J.C., Banga J.D., Moncada S., Palmer R.M., de Groot P.G., and Sixma J.J. Nitric oxide functions as an inhibitor of platelet adhesion under flow conditions. Circulation 85 (1992) 2284-2290
24. Yang Y., and Loscalzo J. Regulation of tissue factor expression in human microvascular endothelial cells by nitric oxide. Circulation 101 (2000) 2144-2148
25. Bryan R.M.J., You J., Golding E.M., and Marrelli S.P. Endothelium-derived hyperpolarizing factor: a cousin to nitric oxide and prostacyclin. Anesthesiology 102 (2005) 1261-1277
26. Yanagisawa M., Kurihara H., Kimura S., Tomobe Y., Kobayashi M., Mitsui Y., Yazaki Y., Goto K., and Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332 (1988) 411-415
27. Kiowski W., Lüscher T.F., Linder L., and Bühler F.R. Endothelin-1-induced vasoconstriction in humans: reversal by calcium channel blockade but not by nitrovasodilators or endothelium-derived relaxing factor. Circulation 83 (1991) 469-475
28. Luscher T.F., and Vanhoutte P.M. Endothelium-derived Relaxing Factors. The Endothelium: Modulator of Cardiovascular Function (1990), CRC Press, Boca Raton, Fla 23-43
29. Vaughan D., Lazos S., and Tong K. Angiotensin regulates the expression of plasminogen activator inhibitor in cultured endothelial cells. J. Clin. Invest. 95 (1995) 995-1001
30. Rajapopalan S., Kurz S., Münzel T., Tarpey M., Freeman B.A., Griendling K.K., and Harrison D.G. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation: contribution to alterations of vasomotor tone. J. Clin. Invest. 97 (1996) 1916-1923
31. Luscher T.F., and Barton M. Biology of the endothelium. Clin. Cardiol. 20 Suppl. 2 (1997) 3-10
32. Vita J.A., and Keaney J.F.J. Endothelial function: a barometer for cardiovascular risk?. Circulation 106 (2002) 640-642
33. Lerman A., and Zeiher A.M. Endothelial function: cardiac events. Circulation 111 (2005) 363-368
34. Gokce N., and Vita J.A. Clinical manifestations of endothelial dysfunction. Thrombosis and Hemorrhage (2002), Lippincott Williams & Wilkins, Philadelphia, PA pp. 685-706
35. Esposito P., Basu S., Letourneau R., Jacobson S., and Theoharides T.C. Corticotropin-releasing factor (CRF) can directly affect brain microvessel endothelial cells. Brain Res. 968 (2003) 192-198
36. Garcia-Villalon A.L., Sanz E., Monge L., Fernandez N., Climent B., and Dieguez G. Urocortin protects coronary endothelial function during ischemia-reperfusion: a brief communication. Exp. Biol. Med. Maywood 22 (2004) 118-120
37. Rademaker M.T., Charles C.J., Espiner E.A., Fisher S., Frampton C.M., Kirkpatrick C.M., Lainchbury J.G., Nicholls M.G., Richards A.M., and Vale W.W. Beneficial hemodynamic, endocrine, and renal effects of urocortin in experimental heart failure: comparison with normal sheep. J. Am. Coll. Cardiol. 40 (2002) 1495-1505
38. Rademaker M.T., Charles C.J., Espiner E.A., Frampton C.M., Lainchbury J.G., and Richards A.M. Endogenous urocortins reduce vascular tone and renin-aldosterone/endothelin activity in experimental heart failure. Eur. Heart J. 26 (2005) 2046-2054
39. Yang C., Xu Y., Mendez T., Wang F., Yang Q., and Li S. Effects of intravenous urocortin on angiotensin-converting enzyme in rats. Vascul. Pharmacol. 44 (2006) 238-246
40. Casadevall M., Saperas E., Panés J., Salas A., Anderson D.C., Malagelada J.R., and Piqué J.M. Mechanisms underlying the anti-inflammatory actions of central corticotropin-releasing factor. Am. J. Physiol. 276 (1999) G1016-G1026
41. Singh L.K., Boucher W., Pang X., Letourneau R., Seretakis D., Green M., and Theoharides T.C. Potent mast cell degranulation and vascular permeability triggered by urocortin through activation of corticotropin-releasing hormone receptors. J. Pharmacol. Exp. Ther. 288 (1999) 1349-1356
42. Kohno M., Kawahito Y., Tsubouchi Y., Hashiramoto A., Yamada R., Inoue K.I., Kusaka Y., Kubo T., Elenkov I.J., Chrousos G.P., Kondo M., and Sano H. Urocortin expression in synovium of patients with rheumatoid arthritis and osteoarthritis: relation to inflammatory activity. J. Clin. Endocrinol. Metab. 86 (2001) 4344-4352
43. Grignani G., and Maiolo A. Cytokines and hemostasis. Haematologica 85 (2000) 967-972
44. Fleisher-Berkovich S., Rimon G., and Danon A. Modulation of endothelial prostaglandin synthesis by corticotropin releasing factor and antagonists. Eur. J. Pharmacol. 353 (1998) 297-302
45. Bale T.L., Giordano F.J., Hickey R.P., Huang Y., Nath A.K., Peterson K.L., Vale W.W., and Lee K.F. Corticotropin-releasing factor receptor 2 is a tonic suppressor of vascularization. Proc. Natl. Acad. Sci. USA 99 (2002) 7734-7739
46. Colasanti M., and Suzuki H. The dual personality of NO. Trends Pharmacol. Sci. 21 (2000) 249-252